BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Personalized Medicine

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

Myeloma

Genomic Testing

1rem

View

A 57-Year-Old Man with Nonmetastatic Castration-Resistant Disease

Videos

Matthew R. Smith, MD, PhD presents a nonmetastatic castration-resistant prostate cancer (CRPC) patient case, discusses how clinical trial data informs his treatment selection, and shares clinical pearls for community oncologists treating patients with CRPC.

Matthew R. Smith, MD, PhD introduces a nonmetastatic castration-resistant prostate cancer (CRPC) patient case featuring a 52-year-old man referred to urology with a PSA of 6.8 ng/mL.

Expert panelist provides his perspective on a CRPC patient case before discussing the typical course of treatment for patients with nonmetastatic CRPC.

Reviewing the Standard of Care for Patients with Nonmetastatic Castration-Resistant Disease

Dr. Smith presents key data concerning the use of darolutamide in patients with castration-resistant CRPC, with a focus on safety and patient quality of life.

The Use of Darolutamide in Patients with Castration-Resistant Prostate Cancer

Mathew R. Smith, MD, PhD closes the discussion by sharing clinical pearls for community oncologists and highlights unmet needs in the CRPC landscape.

The Evolving Castration-Resistant Prostate Cancer Treatment Landscape

Case Based Peer Perspectives

Reviewing the Standard of Care for Patients with Nonmetastatic Castration-Resistant Disease

EP: 1.A 57-Year-Old Man with Nonmetastatic Castration-Resistant Disease

EP: 2.Reviewing the Standard of Care for Patients with Nonmetastatic Castration-Resistant Disease

EP: 3.The Use of Darolutamide in Patients with Castration-Resistant Prostate Cancer

EP: 4.The Evolving Castration-Resistant Prostate Cancer Treatment Landscape

Newsletter